Atlantic Healthcare
Atlantic Healthcare plc is a specialist pharmaceutical company, focused on developing and commercializing therapeutics that address unmet patient needs and rare diseases.
Our work currently focuses on the gastrointestinal (GI) tract and targets the treatment of GI diseases, which have a debilitating effect on the lives of millions of people.
We own the exclusive worldwide rights to alicaforsen, with the potential to establish a new class of treatments for Inflammatory Bowel Disease (IBD) and other GI diseases.
We also own the worldwide rights to renzapride, a molecule with a unique dual mode of action and the potential to treat a variety of GI dysmotility disorders in rare disease patient populations.
Pipeline
Atlantic Healthcare has a diversified late-stage clinical pipeline targeting multiple patient groups and diseases.
| Product | Preclinical | Phase 1 | Phase 2 a | b |
Phase 3 | Regulatory Approval |
| ALICAFORSEN FOR IBD | |||||
| Enema – Ulcerative Colitis |  |
||||
| Tablet – Crohn’s Disease |  |
||||
| Tablet – Ulcerative Colitis | |
||||
| RENZAPRIDE FOR GI DYSMOTILITY | |||||
| Capsule – Systemic Scleroderma |  |
||||
| Capsule – Cystic Fibrosis | |
||||
| Capsule – Parkinson’s Gastroparesis |  |
||||
Find out more
An ambitious, collaborative, cohesive team led by seasoned pharmaceutical executives.
Atlantic Healthcare, founded in 2006, has developed a committed shareholder base and an experienced Board and Leadership Team. To date approximately $50m has been invested in equity and grants.
We know how difficult life can be for patients with inflammatory bowel disease. Our focus is on developing treatments to improve quality of life.